Dexin Corporation (3349) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Dexin Corporation stock TWD 18.23, price TWD 18.40, that is 0.9% below the price, quality 56 out of 100. Rating: fairly valued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
60‑month range 12.20 TWD – 32.00 TWD · fair‑value band 14.75 TWD – 21.94 TWD · the 18.40 TWD price screens above the 18.23 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 3, 2026.
Follow Dexin in your weekly email
Every Wednesday you see whether Dexin is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dexin Corporation engages in the design, development, engineering, manufacture, and sale of entertainment interface devices in Taiwan and internationally.
Show moreShow less
The company offers esports peripherals, such as e-sports mouse, controllers, keyboards, and gaming mouse pad, as well as stylus; and optical products comprising camera modules, vehicle camera modules and media cameras.
It also is involved in the provision of industrial design, research design development, product and manufacture engineering design development, and other customized project design and development services for original equipment and design manufacturers.
The company was founded in 1997 and is headquartered in New Taipei City, Taiwan..
Stock analysis
Dexin Corporation (3349) currently trades at 18.40 TWD, while our model-based Fair Value estimate is 18.23 TWD, so the stock looks roughly fairly valued today (gap 0.9%).
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 23.23 TWD per share, and 6 of the 10 models we run sit above the 18.40 TWD price.
Bear case: the Asset-Based group reads lowest at 3.91 TWD, and 4 of the 10 models stay below the price. Data coverage for this calculation is low.
Scenario range: 14.75 TWD (bear) to 21.94 TWD (bull), the price of 18.40 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Technology sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Dexin Corporation reported revenue of 479M TWD in FY2025 versus 1.2B TWD in FY2021, a compound −21.0%/yr. Reported net income was −43.9M TWD in FY2025.
Key figures
Market cap 848M TWD (≈ $25.8M) Micro · P/S ratio 2.06 · EPS (TTM) −1.19 TWD · Net margin −13.5% · Return on equity −18.6% · Return on assets (EBIT) −6.5% (5-year average) · Operating margin −15.0% · Revenue (TTM) 407M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).
What moves the price
The share trades about 43% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Technology peers we cover trades at −6% fair-value upside, at −1%, 3349 screens cheaper than that median.
Fair Value models
Bear14.75 TWDFair Value 18.23 TWDBull21.94 TWD
Price 18.40 TWD · Downside -0.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF18.06 TWD22.53 TWD30.25 TWD80
Growth DCF18.55 TWD22.83 TWD29.63 TWD77
5Y EBITDA Exit10.27 TWD10.70 TWD11.28 TWD74
All 10 models by family
DCF Models
FCF DCF18.06 TWD22.53 TWD30.25 TWD80
5Y Revenue Exit17.54 TWD23.28 TWD31.61 TWD71
5Y EBITDA Exit10.27 TWD10.70 TWD11.28 TWD74
10Y Revenue Exit17.35 TWD21.45 TWD25.81 TWD66
10Y EBITDA Exit13.50 TWD14.11 TWD14.56 TWD67
Multiples
EV/EBITDA0.2700 TWD0.3100 TWD0.3500 TWD64
EV/Revenue13.92 TWD19.83 TWD25.73 TWD51
Asset-Based
NCAV (Graham)2.58 TWD3.91 TWD4.89 TWD52
Growth DCF
Growth DCF18.55 TWD22.83 TWD29.63 TWD77
Rev-Margin DCF17.54 TWD23.62 TWD31.10 TWD71
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+5.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
2.9% (2020) → −6.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+0.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −1.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Computer Hardware · 213 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−0.9% · Above median
Profitability
Return on assets−8.5% · Bottom 25%
Net margin (12 months)−13.5% · Bottom 25%
Operating margin (12 months)−15.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−21.9% · Bottom 25%
Valuation Multiplesvs Computer Hardware median · lower = cheaper
P/B2.45× · Pricier than median
P/S (12 months)2.08× · Pricier than median
Price / free cash flow (fiscal year)12.2× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Dexin Corporation Fair Value". https://www.fairvalue-calculator.com/stock/3349
Frequently asked questions
Is Dexin Corporation (3349) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 18.23 TWD versus a price of 18.40 TWD, about 1% lower (fairly valued).
What is the fair value of 3349?
Our model-based fair value for Dexin Corporation is 18.23 TWD (as of Nov 3, 2026), built from audited fundamentals. The current price: 18.40 TWD.
What is the quality score of 3349?
Dexin Corporation has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dexin Corporation (3349)?
Our model-based price target is the fair value of 18.23 TWD (as of Nov 3, 2026) from 10 valuation models. Cautious scenario 14.75 TWD, optimistic scenario 21.94 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Dexin Corporation stock forecast for 2026?
Our models put fair value at 18.23 TWD, about 1% lower versus a price of 18.40 TWD (fairly valued). Cautious scenario 14.75 TWD, optimistic scenario 21.94 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Dexin Corporation (3349)?
Dexin Corporation reported trailing-twelve-month revenue of about 407M TWD (latest available figure, as of Nov 3, 2026).
What growth is priced into Dexin Corporation (3349)?
For today's price to be fair in a discounted-cash-flow model, Dexin Corporation would have to grow free cash flow by +0.2 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -10.0 % per year. As of Nov 3, 2026.
What discount rate (WACC) does the fair value of 3349 use?
Our models discount Dexin Corporation at 10.3 %: a base by market capitalisation (nano), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dexin Corporation that is +0.2 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Dexin Corporation (3349) delivered so far?
Over the past 5 years revenue at Dexin Corporation grew -10.0 % a year. The price currently implies free-cash-flow growth of +0.2 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dexin Corporation (3349) growing?
The median revenue growth in the sector is +16.8 % a year. That is the yardstick for the growth priced into Dexin Corporation (+0.2 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dexin Corporation (3349)?
The free-cash-flow yield on the price is 8.23 %: that much free cash flow Dexin Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dexin Corporation (3349)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dexin Corporation it is 18.23 TWD per share (as of Nov 3, 2026), against a price of 18.40 TWD. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Dexin Corporation stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 3349 trades above its calculated fair value: price 18.40 TWD, fair value 18.23 TWD, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 3349?
No. The price is what the market pays today (18.40 TWD); the fair value is what the company's own numbers justify (18.23 TWD). For Dexin Corporation the two are 0.1675 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Dexin Corporation worth?
The market values Dexin Corporation at about 848M TWD (market capitalisation, as of Nov 3, 2026). Per share that is 18.40 TWD; our models calculate a fair value of 18.23 TWD per share.
What do the bullish and bearish scenarios say about 3349?
Our models span a range for Dexin Corporation: cautious scenario 14.75 TWD, base 18.23 TWD, optimistic 21.94 TWD per share (as of Nov 3, 2026, price 18.40 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dexin Corporation (3349)?
Balance-sheet figures for Dexin Corporation (as of Nov 3, 2026): return on equity −18.6%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 3349 from its 52-week high?
Dexin Corporation trades at 18.40 TWD, about 43% below its 52-week high of 32.00 TWD and 4% above the low of 17.70 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 18.23 TWD is for.
Which stocks are comparable to Dexin Corporation?
From the same area (Technology) we also value Dell Technologies Inc, Arista Networks, Inc, Sandisk Corporation, Seagate Technology Holdings, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dexin Corporation stock attractive at the current price?
The data as of Nov 3, 2026: price 18.40 TWD, calculated fair value 18.23 TWD (−1%), Quality Score 56/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 3349 calculated?
We run Dexin Corporation through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 18.23 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Dexin Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dexin Corporation (3349)?
The closing price on Nov 6, 2026 was 18.40 TWD. Our model-based fair value is 18.23 TWD, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dexin Corporation right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Dexin Corporation
How large is the market capitalisation of Dexin Corporation (3349)?
The market capitalisation of Dexin Corporation is 848M TWD (≈ $25.8M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dexin Corporation (3349)?
The price-to-sales ratio of Dexin Corporation is 2.06 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dexin Corporation (3349)?
Earnings per share at Dexin Corporation are −1.19 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Dexin Corporation (3349)?
The net margin of Dexin Corporation is −13.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dexin Corporation (3349)?
The return on equity (ROE) of Dexin Corporation is −18.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dexin Corporation (3349)?
On an EBIT basis the return on assets of Dexin Corporation is −6.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dexin Corporation (3349)?
The operating margin of Dexin Corporation is −15.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dexin Corporation (3349)?
Revenue at Dexin Corporation is growing −21.9% versus a year earlier (3y avg −4.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does Dexin Corporation (3349) hold?
Dexin Corporation holds more cash than debt, 6.7M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Dexin Corporation in the live analysis
One click puts Dexin Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026